Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-06-30 View official record Methodology

Covered recipient · General Payments record

ANN THERESE ESQUIVEL

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1457642597
CMS profile
1406972
Location
ZIONSVILLE, IN

General Payments · PY2019–2025

$7,858.79

  • Reported across 73 records
  • CMS publication 2026-06-30

Latest program year · PY2025

$271.60

13 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2025 · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $271.60 13

By paying entity

PY2025 · sorted by reported total

Paying entityAmountRecords
CSL Behring $62.70 3
Acerta Pharma LLC $55.83 3
HOSPIRA, INC. $36.38 1
GlaxoSmithKline, LLC. $34.96 2
Octapharma USA, Inc. $25.65 1
Amgen Inc. $20.46 1
ARS Pharmaceuticals Operations, Inc. $18.23 1
BioCryst US Sales Co., LLC $17.39 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $193.10 11
PY2020 $105.94 8
PY2021 $6,656.66 11
PY2022 $151.53 8
PY2023 $136.21 6
PY2024 $343.75 16
PY2025 $271.60 13

Payment records · PY2025 (13)

Sorted by paying entity, then date · as published by CMS

Program year 2025 201920202021202220232024 Record-level detail is published for PY2025; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
Amgen Inc. $20.46 08/12/2025 Food and Beverage Undisputed 06/30/2026 1228438830 CMS
ARS Pharmaceuticals Operations, Inc. $18.23 02/20/2025 Food and Beverage Undisputed 06/30/2026 1245873572 CMS
AstraZeneca Pharmaceuticals LP $22.03 05/13/2025 Food and Beverage Undisputed 06/30/2026 1206863703 CMS
AstraZeneca Pharmaceuticals LP $13.50 08/26/2025 Food and Beverage Undisputed 06/30/2026 1206354515 CMS
AstraZeneca Pharmaceuticals LP $20.30 12/18/2025 Food and Beverage Undisputed 06/30/2026 1206917360 CMS
BioCryst US Sales Co., LLC $17.39 12/10/2025 Food and Beverage Undisputed 06/30/2026 1222028234 CMS
CSL Behring $16.67 02/04/2025 Food and Beverage Undisputed 06/30/2026 1232358153 CMS
CSL Behring $24.68 05/30/2025 Food and Beverage Undisputed 06/30/2026 1232358171 CMS
CSL Behring $21.35 10/28/2025 Food and Beverage Undisputed 06/30/2026 1232358191 CMS
GlaxoSmithKline, LLC. $18.46 01/09/2025 Food and Beverage Undisputed 06/30/2026 1191353330 CMS
GlaxoSmithKline, LLC. $16.50 04/08/2025 Food and Beverage Undisputed 06/30/2026 1191646149 CMS
HOSPIRA, INC. $36.38 03/20/2025 Food and Beverage Undisputed 06/30/2026 1228900839 CMS
Octapharma USA, Inc. $25.65 07/01/2025 Food and Beverage Undisputed 06/30/2026 1245077137 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.